Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-1,99
KB0,90
PKN65,1165,142,13
Msft420,72420,74-0,17
Nokia3,29053,2965-1,02
IBM190,73190,75-0,04
Mercedes-Benz Group AG73,8573,870,39
PFE27,8627,870,29
28.03.2024 19:50:00
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024 12:56:17
Nektar Therap (NKTR.F, Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
0,7798 -3,70 -0,03 4 012
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.03.2024
Popis společnosti
Obecné informace
Název společnostiNektar Therapeutics
TickerNKTR
Kmenové akcie:Ordinary Shares
RICNKTR.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 137
Akcie v oběhu k 27.02.2024 183 617 817
MěnaUSD
Kontaktní informace
Ulice455 Mission Bay Boulevard South
MěstoSAN FRANCISCO
PSČ94158
ZeměUnited States
Kontatní osobaVivian Wu
Funkce kontaktní osobyAssociate Director, Investor Relations and Corporate Affairs
Telefon14 154 825 300
Fax14153395300
Kontatní telefon16 288 950 661

Business Summary: Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Nektar Therapeutics revenues decreased 2% to $90.1M. Net loss decreased 25% to $276.1M. Revenues reflect Rest of world segment decrease of 4% to $78.6M. Lower net loss reflects Research and development - Balancing val decrease of 47% to $100.3M (expense), Restructuring, impairment and other decrease of 77% to $15.3M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 28.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorHoward Robin7014.02.200715.01.2007
Interim Chief Financial OfficerSandra Gardiner5717.04.202317.04.2023
Senior Vice President, Chief Legal OfficerMark Wilson51
Chief Medical OfficerMary Tagliaferri5817.04.2023
Chief Research and Development OfficerJonathan Zalevsky4801.10.201901.10.2019